Firstly, noone, including Imugene, would offer 10x the current price.
And second, I don't think Imugene would be at all interested in acquiring Chimeric.They have everything they need already, and if they were looking for more assets it would likely be CD19 directed therapies to complement their OnCARlytics platform.
I think that is why Arovella has been pumped so hard, speculation of a buyout/licensing from Imugene.
Charting Only, page-363
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.951M | |||
| Open | High | Low | Value | Volume |
| 1.1¢ | 1.2¢ | 1.0¢ | $38.54K | 3.639M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 2646760 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 729690 | 4 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| CHM (ASX) Chart |